Evidence map›Paper›PMID 36523267›Full record

ArticleBrain communications2022

Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model.

Clare I Campbell, Rhona McGonigal, Jennifer A Barrie, Jolien Delaere, Laura Bracke, Madeleine E Cunningham, Denggao Yao, Tim Delahaye, Inge Van de Walle, Hugh J Willison

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Guillain-Barré syndrome: a comprehensive review.European journal of neurology · 2024
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Clare I CampbellInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Rhona McGonigalInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Jennifer A BarrieInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Jolien Delaereargenx BV, Zwijnaarde, 9052 Ghent, Belgium.
Laura Brackeargenx BV, Zwijnaarde, 9052 Ghent, Belgium.
Madeleine E CunninghamInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Denggao YaoInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Tim Delahayeargenx BV, Zwijnaarde, 9052 Ghent, Belgium.
Inge Van de Walleargenx BV, Zwijnaarde, 9052 Ghent, Belgium.ORCID https://orcid.org/0000-0002-7631-399X
Hugh J WillisonInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.ORCID https://orcid.org/0000-0002-5997-1683
University of Glasgow · GBAblynx (Belgium) · BE

Funding

Wellcome Trust 202789/Z/16/Z
6 · The paper itself

Abstract

The involvement of the complement pathway in Guillain-Barré syndrome pathogenesis has been demonstrated in both patient biosamples and animal models. One proposed mechanism is that anti-ganglioside antibodies mediate neural membrane injury through the activation of complement and the formation of membrane attack complex pores, thereby allowing the uncontrolled influx of ions, including calcium, intracellularly. Calcium influx activates the calcium-dependent protease calpain, leading to the cleavage of neural cytoskeletal and transmembrane proteins and contributing to subsequent functional failure. Complement inhibition has been demonstrated to provide effective protection from injury in anti-ganglioside antibody-mediated mouse models of axonal variants of Guillain-Barré syndrome; however, the role of complement in the pathogenesis of demyelinating variants has yet to be established. Thus, it is currently unknown whether complement inhibition would be an effective therapeutic for Guillain-Barré syndrome patients with injuries to the Schwann cell membrane. To address this, we recently developed a mouse model whereby the Schwann cell membrane was selectively targeted with an anti-GM1 antibody resulting in significant disruption to the axo-glial junction and cytoplasmic paranodal loops, presenting as conduction block. Herein, we utilize this Schwann cell nodal membrane injury model to determine the relevance of inhibiting complement activation. We addressed the early complement component C2 as the therapeutic target within the complement cascade by using the anti-C2 humanized monoclonal antibody, ARGX-117. This anti-C2 antibody blocks the formation of C3 convertase, specifically inhibiting the classical and lectin complement pathways and preventing the production of downstream harmful anaphylatoxins (C3a and C5a) and membrane attack complexes. Here, we demonstrate that C2 inhibition significantly attenuates injury to paranodal proteins at the node of Ranvier and improves respiratory function in

Indexed as

axo-glial junctioncomplement inhibitionglial membrane injuryGuillain–Barré syndromeparanodal loops

Identifiers

PMID36523267
PMCPMC9746686
OpenAlexW4309842763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.